Trial Profile
T-Cell PET Imaging With [18F]F-AraG and Radiomics to Guide Combined Radiation and Systemic Immune Modulating Therapies
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs 18F-F-AraG (Primary) ; Pembrolizumab
- Indications Non-small cell lung cancer
- Focus Diagnostic use
- 17 Oct 2019 Planned End Date changed from 1 Dec 2020 to 15 Oct 2019.
- 17 Oct 2019 Planned primary completion date changed from 1 Dec 2019 to 15 Oct 2019.
- 17 Oct 2019 Status changed from recruiting to withdrawn prior to enrolment.